U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 11 - 20 of 21 results

Status:
Possibly Marketed Outside US
Source:
NCT04619927: Phase 4 Interventional Recruiting Peripheral Arterial Disease
(2021)
Source URL:

Class:
PROTEIN

Status:
Possibly Marketed Outside US
Source:
NCT02710747: Phase 4 Interventional Unknown status Heart Valve Disease
(2015)
Source URL:

Class:
PROTEIN

structurally diverse
Status:
Other

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Other

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
Other

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Approved Allergenic Extract (1972)

Class:
STRUCTURALLY DIVERSE

structurally diverse
Status:
US Approved Allergenic Extract (1974)
First marketed in 1921
Source:
Capsicum U.S.P.
Source URL:

Class:
STRUCTURALLY DIVERSE

Capsaicin is a topical analgesic that is FDA approved for the treatment of neuropathic pain associated with postherpetic neuralgia. Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. Capsaicin is an agonist for the transient receptor potential vanilloid I receptor (TRPVI), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Common adverse reactions include erythema, rash, pruritus, nausea.

Showing 11 - 20 of 21 results